Association Study between Genes Related to Pharmacokinetics andPharmacodynamics of Oxycodone and Response to Drug Treatment: AGenetic Cohort Study
2019
Objective: Oxycodone is widely used in cancer patients with pain, but interindividual differences in both its analgesic
efficacy and adverse effects are major clinical disadvantages to therapeutic use. To explore specific polymorphisms
affecting drug plasma concentrations, analgesic efficacy, and adverse effects, we performed an association study
between genetic polymorphisms affecting pharmacokinetics and pharmacodynamics of oxycodone and response to
drug treatment in cancer patients with pain.
Methods: Blood samples were collected from 50 patients 12 h after administration of oxycodone. Genetic
polymorphisms related to the pharmacokinetics and pharmacodynamics of oxycodone [cytochrome P450
(CYP3A4*1G, CYP3A5*3, and CYP2D6*10), P-glycoprotein (ABCB1), and opioid receptor μ1 (OPRM1)] were
genotyped by real-time polymerase chain reaction (PCR) and plasma concentrations of oxycodone and noroxycodone
were determined by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
Results: Carriers of specific polymorphisms (CYP3A4 *1G/*1G, CYP3A5 *1/*1, CYP2D6 100CC+CT, and
ABCB1 2677TA+TT+AA) were associated with increased average total daily dose of oxycodone. CYP3A4 *1G/*1G
and CYP3A5 *1/*1 were also associated with increased number of rescues and plasma concentration of oxycodone.
Moreover, OPRM1 118AG+GG carriers were related to greater average total daily dose of oxycodone and increased
number of rescues.
Conclusion: These findings suggest that genetic polymorphisms of genes related to pharmacokinetics and
pharmacodynamics of oxycodone have a potential impact on clinical responses to drug in cancer patients with pain.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI